Variability in the management of GLP-1 agonists and endoscopic procedures: an opportunity for standardization

No SJR dataJan 15, 2025Revista espanola de enfermedades digestivas

Differences in how GLP-1 medicines and endoscopic treatments are used suggest a need for standard guidelines

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗

Abstract

GLP-1 receptor agonists may lead to weight losses of up to 20% of baseline body weight.

GLP-1 receptor agonists are effective treatments for type 2 diabetes and obesity.
These medications are being studied for potential benefits in metabolic-associated liver disease, cardiovascular disorders, neurocognitive impairments, and some addictions.
The emerging effects of GLP-1 receptor agonists may be related to their metabolic actions and their impact on chronic inflammation.

AI simplified

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), also known as incretin mimetics, have significantly revolutionized the treatment of type 2 diabetes mellitus (T2DM) and obesity worldwide, far exceeding initial expectations regarding their global prescription. This class of medications has demonstrated weight losses of up to 20 % of baseline body weight. Beyond their proven benefits in T2DM and obesity, GLP-1RAs, as well as dual and triple agonists (GLP-1/GIP/glucagon), are being investigated for their effects on conditions such as metabolic-associated steatotic liver disease, various cardiovascular disorders, neurocognitive impairments, and certain addictions. These emerging effects appear to be linked not only to their metabolic action but also to their ability to modulate the chronic inflammatory state underlying these pathologies.

Abstract

Related papers